The mycoses market is anticipated to show substantial growth during the forecast period of 2021-2031 owing to the rising incidences of fungal infections across the globe. Mycoses are fungal infections that cause chronic diseases or multiple organ failures. It is mainly caused due to weak immune systems. The cause of mycoses is the multiplication of fungi in certain parts of the body, especially the outer skin, body, or scalp. It can be cured with proper medication and diagnostics. The population residing in unclean spaces is vulnerable to such infections owing to poor hygiene conditions. Furthermore, the increasing geriatric population is also prone to get affected by mycoses. All these aspects may promote the growth of the mycoses market.
The mycoses market can be segmented into azoles, echinocandins, polyenes, allylamines, and others based on drug class. By route of administration the market can be segmented into topical, oral, and others. On the basis of fungi type, the mycoses market can be segmented into yeasts, molds, and others. Based on distribution channels it can be divided into hospital, retail, and online pharmacy. The end-users in the mycoses market can be homecare, specialty clinics, hospitals, and others.
The experienced team at TMR has curated this report based on various parameters such as current trends, key drivers, developments, regional perspective, and competitive analysis. The in-depth analysis of the key areas gives a clear picture of the mycoses market to the stakeholders and CXOs so that they can take proper decisions.
The key players operating in the mycoses market are indulging in informative research to formulate new drugs and therapeutics for the treatment of mycoses. The key players are involved in the process of taking approvals and launching new products to provide effective treatment to the patients suffering from mycoses.
The market players are collaborating through mergers, acquisitions, joint ventures, partnerships, and startups to expand their market reach. The clinical trials are being conducted efficiently to incorporate new treatment procedures. These developments may augment the growth of the mycoses market.
Some of the key players operating in the market are Teva Pharmaceutical Industries Ltd, Pfizer Inc, Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma, Novartis AG, Lannett, Mylan N.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, and Lupin.
The rising prevalence of chronic and infectious diseases across the globe has led to the growth of the mycoses market. The increasing incidences of diseases such as HIV and cancer may increase the infections caused by mycoses. Further, the growing geriatric population is likely to get infected with mycoses may boost the market growth.
The preferences for laser therapy and drug medication have shown significant growth over a period of time. The efficacy of the treatment procedures is likely to propel the growth of the mycoses market.
During the COVID-19 pandemic, the supply chain was disrupted but the production of drugs and the treatment procedures were not affected. However, the online sales channel proved to be a growth booster for the mycoses market.
The global market is segmented into Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe based on the regions. North America is expected to generate substantial revenue in the global market owing to the increasing incidences of AIDS/HIV across this region. Europe may follow North America due to the increasing prevalence of mycoses in this region. Furthermore, Asia Pacific may witness substantial growth due to the expanding development of novel therapeutics and drugs in this region. All these factors are likely to create immense growth opportunities for the global mycoses market.